GlaxoSmithKline Pakistan Limited (PSX:GLAXO)
Pakistan · Delayed Price · Currency is PKR 337.31
-2.70 (-0.79%)
At close: Nov 6, 2026
GlaxoSmithKline Pakistan Ratios and Metrics
Market cap in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 107,422 | 124,132 | 126,403 | 26,430 | 27,952 | 43,474 | |
Market Cap Growth | -14.86% | -1.80% | 378.26% | -5.45% | -35.70% | -28.84% |
Enterprise Value | 99,615 | 117,492 | 119,878 | 22,631 | 20,591 | 38,013 |
Last Close Price | 340.01 | 369.59 | 363.66 | 76.04 | 80.42 | 118.85 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.78 | 12.38 | 19.34 | 49.50 | 11.35 | 8.12 |
Forward PE | 9.77 | 10.86 | - | - | - | - |
PS Ratio | 1.56 | 1.88 | 2.07 | 0.53 | 0.67 | 1.19 |
PB Ratio | 3.11 | 3.69 | 4.47 | 1.22 | 1.33 | 2.07 |
P/TBV Ratio | 3.20 | 3.79 | 4.63 | 1.28 | 1.39 | 2.17 |
P/FCF Ratio | 17.19 | 20.41 | 55.38 | 112.68 | - | 11.80 |
P/OCF Ratio | 12.62 | 14.33 | 24.99 | 14.03 | - | 8.72 |
PEG Ratio | - | 0.47 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.45 | 1.78 | 1.96 | 0.46 | 0.49 | 1.04 |
EV/EBITDA Ratio | 5.21 | 6.64 | 10.57 | 7.85 | 3.48 | 4.98 |
EV/EBIT Ratio | 5.65 | 7.18 | 11.69 | 11.52 | 4.06 | 5.53 |
EV/FCF Ratio | 15.95 | 19.32 | 52.52 | 96.49 | - | 10.32 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.02 | 0.01 | 0.03 | 0.02 | 0.01 |
Debt / EBITDA Ratio | 0.02 | 0.03 | 0.03 | 0.25 | 0.06 | 0.04 |
Debt / FCF Ratio | 0.05 | 0.10 | 0.16 | 3.09 | - | 0.08 |
Net Debt / Equity Ratio | -0.22 | -0.24 | -0.22 | -0.13 | -0.21 | -0.40 |
Net Debt / EBITDA Ratio | -0.40 | -0.45 | -0.54 | -1.00 | -0.75 | -1.10 |
Net Debt / FCF Ratio | -1.24 | -1.31 | -2.69 | -12.30 | 0.94 | -2.29 |
Asset Turnover | 1.33 | 1.38 | 1.47 | 1.35 | 1.27 | 1.30 |
Inventory Turnover | 2.50 | 3.40 | 3.95 | 4.30 | 4.20 | 4.24 |
Quick Ratio | 1.13 | 1.35 | 1.17 | 0.83 | 0.92 | 1.41 |
Current Ratio | 2.20 | 2.32 | 2.06 | 1.74 | 1.82 | 2.28 |
Return on Equity (ROE) | 34.03% | 32.37% | 26.17% | 2.50% | 11.72% | 27.84% |
Return on Assets (ROA) | 21.47% | 21.36% | 15.40% | 3.33% | 9.60% | 15.20% |
Return on Invested Capital (ROIC) | 40.26% | 41.11% | 31.26% | 2.72% | 16.74% | 40.71% |
Return on Capital Employed (ROCE) | 49.50% | 46.00% | 34.00% | 8.30% | 22.40% | 31.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 10.22% | 8.08% | 5.17% | 2.02% | 8.81% | 12.32% |
FCF Yield | 5.82% | 4.90% | 1.81% | 0.89% | -16.79% | 8.47% |
Dividend Yield | 5.63% | 4.36% | 2.52% | - | - | 5.13% |
Payout Ratio | 54.74% | 47.30% | 0.03% | 345.56% | 15.23% | 38.51% |
Total Shareholder Return | 5.57% | 4.36% | 2.52% | - | - | 5.13% |